Literature DB >> 24622370

Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study.

Pia R Kamstrup1, Børge G Nordestgaard2.   

Abstract

BACKGROUND: Low concentrations of lipoprotein(a) in plasma are associated with increased risk of type 2 diabetes, but whether this association is causal is unclear. Variations in the LPA gene affect lipoprotein(a) isoform size and concentrations in plasma. We therefore did a Mendelian randomisation study to investigate whether large isoform size, low concentrations in plasma, or both, are causally associated with type 2 diabetes.
METHODS: We assessed data for adults from the Danish general population enrolled in the Copenhagen City Heart Study and the Copenhagen General Population Study, with and without type 2 diabetes. Eligible participants had data for lipoprotein(a) concentrations in plasma, LPA kringle IV type 2 (KIV-2) sums of repeats (affecting both isoform size and plasma concentrations), and carrier status for the LPA single-nucleotide polymorphism rs10455872 (mainly affecting concentrations in plasma).
FINDINGS: 77,901 individuals had lipoprotein(a) data, of whom 28,567 (36·7%) had all three measurements. Low concentrations of lipoprotein(a) in plasma were associated with risk of type 2 diabetes, with adjusted odds ratios of 1·26 (1·09-1·45), 1·17 (1·01-1·36), 1·04 (0·90-1·21), and 1·05 (95% CI 0·90-1·22), respectively, for quintiles 1-4, compared with quintile 5 concentrations. High KIV-2 sums of repeats were associated with risk of type 2 diabetes (adjusted odds ratio 1·16, 95% CI 1·05-1·28) for KIV-2 quintile 5 versus quintiles 1-4 combined. Being a carrier of rs10455872 did not affect risk of type 2 diabetes. For a halving of lipoprotein(a) concentrations, the instrumental variable estimate of the causal odds ratio for type 2 diabetes was 1·15 (95% CI 1·05-1·27) for KIV-2 sum of repeats and 0·99 (0·95-1·03) for rs10455872 genotype.
INTERPRETATION: Low lipoprotein(a) concentrations alone seem not to be causally associated with type 2 diabetes, but a causal association for large lipoprotein(a) isoform size cannot be excluded. FUNDING: Danish Heart Foundation, Danish Council for Independent Research-Medical Sciences, IMK Almene Fund, and Johan and Lise Boserup's Fund.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24622370     DOI: 10.1016/S2213-8587(13)70064-0

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  33 in total

Review 1.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

2.  Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Authors:  Lin Ding; An Song; Meng Dai; Min Xu; Wanwan Sun; Baihui Xu; Jichao Sun; Tiange Wang; Yu Xu; Jieli Lu; Weiqing Wang; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2015-02-03       Impact factor: 5.922

Review 3.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 4.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

5.  LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk.

Authors:  Di-Li-Da-Er Mu-Han-Ha-Li 迪丽达尔 木汗哈力; Tian-Yu Zhai 翟天羽; Yan Ling 凌雁; Xin Gao 高鑫
Journal:  J Lipid Res       Date:  2018-03-06       Impact factor: 5.922

6.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

Review 7.  Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.

Authors:  Parth Shah
Journal:  Curr Cardiol Rep       Date:  2018-05-19       Impact factor: 2.931

Review 8.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

9.  Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Authors:  Renu Nandakumar; Anastasiya Matveyenko; Tiffany Thomas; Marianna Pavlyha; Colleen Ngai; Stephen Holleran; Rajasekhar Ramakrishnan; Henry N Ginsberg; Wahida Karmally; Santica M Marcovina; Gissette Reyes-Soffer
Journal:  J Lipid Res       Date:  2018-10-07       Impact factor: 5.922

Review 10.  Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.

Authors:  Sotirios Tsimikas
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.